secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longeveron Inc. (LGVN)
CIK:        0001721484
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001213900-25-041066
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Longeveron Q1 net loss $5.0M; HLHS trial 95% enrolled, BLA on track for 2026
----------------------------------------------------------------------------

- Q1 2025 net loss $5.0M (up 23% YoY) on revenue $0.4M (down 30%); cash $14.3M, funding late into Q3 2025.
- HLHS pivotal trial ELPIS II ~95% enrolled, completion Q2 2025; BLA submission for full traditional approval anticipated in 2026.
- CLEAR MIND Alzheimer's Phase 2a results published in Nature Medicine; FDA agreed on pivotal Phase 2/3 trial design for BLA.
- Company plans to seek additional financing and partnerships for BLA readiness and Alzheimer's program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1721484/000121390025041066/0001213900-25-041066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1721484/000121390025041066/ea0241148-8k_longeveron.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-041066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer